NCT00124189 - Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Chronic Lymphoproliferative Diseases

Interventions

DRUG

GRN163L

Weekly intravenous infusion

Trial Locations (8)

Weill Medical College of Cornell University, New York

Long Island Jewish Medical Center, New Hyde Park

Roswell Park Cancer Center, Buffalo

The Ohio State University James Cancer Hospital, Columbus

UT Southwestern, Dallas

University of Texas Health Science Center, San Antonio

Rocky Mountain Cancer Center, Denver

Hackensack University Medical Center, Hackensack